Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Eton Pharmaceuticals Fourth Quarter 2025 Earnings Call - DESMODA launch widens market and fuels aggressive $200M by-2027 growth target
Eton closed 2025 with a fast-moving playbook: three relaunches plus a new FDA-approved liquid desmopressin, an opportunistic M&A add, and materially higher margins. Q4 product sales hit $21.3 million,...
- Q4 2025 product revenue was $21.3 million, up 83% year-over-year, driven by Alkindi plus contributions from Increlex, Galzin, and KHINDIVI.
- Eton says 2025 revenue more than doubled versus 2024, and management expects 2026 revenue to exceed $110 million with adjusted EBITDA margin of at least 30%.
- DESMODA, an FDA-approved oral liquid desmopressin for central diabetes insipidus, received approval end of February, launched within two weeks, and carries a clean label with no age restriction.
- +14 more takeaways
GrowGeneration Q4 and Full Year 2025 Earnings Call - Private Label Push, Cost Cuts Put Break-Even Adjusted EBITDA in Reach for 2026
GrowGeneration spent 2025 reshaping itself from a store-heavy retailer into a lean, brand-led B2B supplier. The company closed stores, cut roughly $27 million of operating costs, and pushed proprietar...
- Full year 2025 net sales were $161.7 million, down from $188.9 million in 2024, primarily because of store consolidations.
- Q4 2025 net sales were $37.8 million, up $0.4 million year-over-year despite operating with eight fewer retail locations, signaling stabilization of core revenue.
- Gross margin expanded 370 basis points to 26.8% for full year 2025, and Q4 gross margin rose to 24.1% from 16.4% a year earlier, driven mainly by higher proprietary brand penetration and fewer restructuring charges.
- +16 more takeaways
Intellicheck Q4 2025 Earnings Call - Annual GAAP Profitability and EBITDA Positive as AWS Migration Boosts Margins
Intellicheck closed 2025 with a clean, profitable finish, reporting Q4 revenue of $6.635 million and full-year revenue of $22.67 million, up 12% and 13% respectively. Management emphasized the move to...
- Q4 2025 revenue was $6.635 million, full-year revenue reached a record $22.67 million, up 12% and 13% year-over-year respectively.
- Intellicheck reported full-year GAAP net income of $1.273 million, reversing a $918,000 loss in 2024.
- Adjusted EBITDA was $1.877 million in Q4 and $2.566 million for 2025, roughly five times 2024's annual adjusted EBITDA.
- +12 more takeaways
electroCore Q4 and Full Year 2025 Earnings Call - CEO Retirement; Record Revenue Led by VA, Profitability Still Distant
electroCore closed 2025 with its highest quarterly revenue ever, driven by expanded adoption in the VA system and a fast-growing Truvaga wellness channel. Management announced a planned CEO retirement...
- CEO Dan Goldberger will retire effective April 1, 2026, with CFO Joshua Lev named interim president while remaining CFO.
- Board hired Michael Fox as Chief Operating Officer, joining in April; Fox brings decades of federal channel experience intended to accelerate VA and other federal sales.
- Q4 2025 revenue hit a record $9.2 million, up 31% year-over-year; full year 2025 revenue was $32.0 million, up 27% versus 2024.
- +16 more takeaways
Tenon Medical Q4 2025 Earnings Call - SImmetry+ Clearance Spurs Q4 Revenue Surge as Multi-Product Play Begins
Tenon closed 2025 with clear commercial momentum, reporting record full-year revenue of $3.9 million, up 20% year over year, and a breakout fourth quarter at $1.5 million, up 92% from Q4 2024. Managem...
- Record full-year revenue of $3.9 million for 2025, a 20% increase versus 2024; Q4 revenue was $1.5 million, up 92% year over year.
- Management credits back-half 2025 momentum and new physician users across Catamaran and SImmetry+ for the revenue gains.
- Tenon received FDA 510(k) clearance for the next-generation SImmetry+ SI joint fusion system, adding a lateral approach to its portfolio.
- +12 more takeaways
Curis Q4 2025 Earnings Call - PCNSL Take Aim registrational study on track for accelerated submissions
Curis reported steady clinical progress and a cleaner balance sheet in Q4 2025. The company reiterated that its Take Aim Lymphoma registrational trial in primary CNS lymphoma is enrolling on plan, wit...
- Take Aim Lymphoma is a single-arm registrational study in primary CNS lymphoma evaluating emavusertib plus ibrutinib with an ORR endpoint, intended to support accelerated submissions in the U.S. and Europe after FDA and EMA discussions.
- Company says enrollment in the PCNSL trial is on track, but cautions patient accrual is choppy given the rarity of the indication, estimating full enrollment in roughly 12 to 18 months.
- Curis is prioritizing NHL programs, specifically PCNSL for registration and CLL for proof of concept, ahead of further investment in AML.
- +11 more takeaways
Mount Logan Capital Q4 and Full Year 2025 Earnings Call - Yieldstreet Deal to Nearly Double SOFIX and Add ~30% to FRE
Mount Logan spent 2025 remaking itself: redomiciled to the US, moved to Nasdaq under ticker MLCI, converted to US GAAP, closed the 180 Degree Capital business combination, and built a credit-focused p...
- 2025 was transformational: Mount Logan redomiciled to the US, converted from IFRS to US GAAP, listed on Nasdaq (MLCI), and completed the 180 Degree Capital business combination, creating a credit-focused asset management and insurance platform.
- Company-reported total assets under management are about $2.1 billion, with insurance or insurance-related AUM around $1.1 billion after repositioning Ability.
- Management announced a definitive agreement for SOFIX to acquire the Yieldstreet Alternative Income Fund portfolio, a deal expected to add over $100 million to SOFIX net assets and nearly double that vehicle.
- +15 more takeaways
Kolibri Global Energy Q4 2025 Earnings Call - 15% production growth, cautious but flexible drilling plan as prices climb
Kolibri delivered a year of operational momentum despite a brutal price backdrop. Production rose 15% to 4,013 BOE per day in 2025, with December topping 5,600 BOE/d, driving a three-year compound ann...
- Production up 15% in 2025 to 4,013 BOE/day, December production exceeded 5,600 BOE/day; three-year production CAGR is ~35%.
- Operating expense per BOE improved to $7.33 in 2025 from $7.44 in 2024, signalling continued operational efficiency.
- Net revenue fell to $56.9 million, down 3% year over year, driven by a steep decline in realized prices during 2025.
- +10 more takeaways
Gold Royalty Corp. Q4 2025 Earnings Call - Record revenue, positive free cash flow and Pedra Branca acquisition fuels growth
Gold Royalty closed 2025 with record quarterly and full-year revenue and adjusted EBITDA, a third consecutive quarter of positive free cash flow, and a materially strengthened balance sheet after a $1...
- Q4 2025 results set new records: adjusted EBITDA of $3.2 million and total revenue, land agreement proceeds and interest of $5.2 million (1,255 GEO in the quarter).
- Full-year 2025: $17.8 million in total revenue and $9.8 million of adjusted EBITDA, up 38% and 104% year over year respectively.
- Third consecutive quarter of positive free cash flow, which management says establishes a self-funding foundation for growth.
- +12 more takeaways
Aveanna Healthcare Holdings Fourth Quarter 2025 Earnings Call - Preferred payer push and rate gains are normalizing volumes and margins
Aveanna closed 2025 with clear evidence that its preferred payer strategy and targeted rate wins are converting into revenue, margin and cash flow recovery, even as the company continues to wrestle wi...
- Q4 revenue was $662.5 million, up 27.4% year over year; full year 2025 revenue was $2.433 billion, up 20.2%.
- Q4 Adjusted EBITDA was $85 million, up 54% year over year; full year 2025 Adjusted EBITDA was $320.8 million, up 74.8%.
- Results benefitted from a 53rd week in the fiscal year, which boosted revenue and earnings versus a typical year.
- +16 more takeaways